Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
|Articles|May 4, 2022
Daily Medication Pearl: Aripiprazole Lauroxil (Aristada)
Author(s)Saro Arakelians, PharmD
Aripiprazole Lauroxil (Aristada) is a long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults.
Advertisement
Medication Pearl of the Day: Aripiprazole Lauroxil (Aristada)
Indication: Aripiprazole Lauroxil(Aristada) is a long-acting injectable atypical antipsychotic indicated for the treatment of schizophrenia in adults.
Insight:
- Dosing: Administer aripiprazole lauroxil by intramuscular injection in the deltoid (441 mg dose only) or gluteal (441 mg, 662 mg, 882 mg or 1064 mg) muscle by a health care professional.
- Dosage forms: Extended-release injectable suspension 441 mg, 662 mg, 882 mg, or 1064 mg single-dose pre-filled syringe.
- Adverse events: The most frequently observed adverse reaction with aripiprazole lauroxil (incidence ≥5% and at least twice that for placebo) was akathisia.
- Mechanism of action: Aripiprazole lauroxil is a prodrug of aripiprazole. Following intramuscular injection, aripiprazole lauroxil is likely converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. The mechanism of action of aripiprazole in schizophrenia is unknown. However, efficacy could be mediated through a combination of partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at 5-HT2A receptors.
- Manufacturer: Alkermes
Reference
Advertisement
Related to this article
Marie-Claire Seeley, RN, MNurs, PhD, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
Novo Nordisk's top-line phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
Engineered Stem Cell Therapy Reverses New-Onset T1D in Mice by Reprogramming T Cells
3
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
4
CKD Prevalence Unmoved Despite Billions in Virtual Care
5